ENTRY       D05697                      Drug
NAME        Ranibizumab (USAN/INN);
            Ranibizumab (genetical recombination) (JAN);
            Ranibizumab (genetical recombination) [Ranibizumab biosimilar 1] (JAN);
            Ranibizumab-nuna;
            Lucentis (TN);
            Byooviz (TN);
            Susvimo (TN);
            Ximluci (TN)
PRODUCT     BYOOVIZ (BIOGEN)
            CIMERLI (Coherus BioSciences)
            LUCENTIS (Genentech)
            SUSVIMO (Genentech)
FORMULA     C2158H3282N562O681S12
EXACT_MASS  48349.6111
MOL_WEIGHT  48379.2865
REMARK      Therapeutic category: 1319
            ATC code: S01LA04
            Product: D05697<JP/US>
EFFICACY    Angiogenesis inhibitor, Anti-VEGF antibody
  DISEASE   Age-related macular degeneration [DS:H00821]
            Macular edema following retinal vein occlusion [DS:H01651]
            Diabetic retinopathy [DS:H01457]
  TYPE      Monoclonal antibody
TARGET      VEGFA [HSA:7422] [KO:K05448]
  PATHWAY   hsa04370(7422)  VEGF signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             S SENSORY ORGANS
              S01 OPHTHALMOLOGICALS
               S01L OCULAR VASCULAR DISORDER AGENTS
                S01LA Antineovascularisation agents
                 S01LA04 Ranibizumab
                  D05697  Ranibizumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Ophthalmic Agents
              Ophthalmic Agents, Other
               Vascular Endothelial Growth Factor (VEGF) Inhibitor
                Ranibizumab
                 D05697  Ranibizumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              13  Agents affecting sensory organs
               131  Ophthalmic agents
                1319  Others
                 D05697  Ranibizumab (USAN/INN); Ranibizumab (genetical recombination) (JAN); Ranibizumab (genetical recombination) [Ranibizumab biosimilar 1] (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                VEGFA
                 D05697  Ranibizumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D05697
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05697
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05697
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D05697
DBLINKS     CAS: 347396-82-1
            PubChem: 47207358
            NIKKAJI: J2.229.654J
///
